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Abstract
Hepatitis C virus (HCV) establishes a chronic infection in the majority of exposed individuals and 
can cause cirrhosis and hepatocellular carcinoma. The role of antibodies directed against HCV in 
disease progression is poorly understood. Neutralizing antibodies (nAbs) can prevent HCV 
infection in vitro and in animal models. However, the effects of nAbs on an established HCV 
infection are unclear. Here, we demonstrate that three broadly nAbs, AR3A, AR3B and AR4A, 
delivered with adeno-associated viral (AAV) vectors can confer protection against viral challenge 
in humanized mice. Furthermore, we provide evidence that nAbs can abrogate an ongoing HCV 
infection in primary hepatocyte cultures and in a human liver chimeric mouse model. These results 
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showcase a novel therapeutic approach to interfere with HCV infection exploiting a previously 
unappreciated need for HCV to continuously infect new hepatocytes in order to sustain chronicity.
Introduction
HCV chronically infects at least 170 million worldwide, and until recently curative therapies 
were poorly tolerated and ineffective in the majority of patients(1). HCV is among the few 
viruses causing human pathology that either establishes a chronic infection or is 
spontaneously cleared. Although an essential function for T cells in HCV clearance is 
widely accepted, the role of antibodies in controlling HCV infection remains elusive. 
Individuals almost universally seroconvert 2–10 months after infection(2) but it remains 
controversial if early development of neutralizing antibodies (nAb) predicts viral 
clearance(3–6). In addition, there are several case reports of seropositive patients who were 
successfully cured of their HCV and subsequently became re-infected(7). Moreover, 
chimpanzees that spontaneously resolved HCV infection remain susceptible to homologous 
re-challenge(8). These observations suggest that naturally arising immunity does not 
universally protect from reinfection. Failure of the immune system to protect from re-
challenge can be explained in part by HCV’s remarkable genetic diversity and high 
proliferative rate readily yielding mutations that allow the virus to escape from immune 
pressure(9). In vitro experiments in human hepatoma cell lines suggest that the effect of 
antibodies on ongoing infection may be further diminished by HCV’s ability to spread 
directly from cell-to-cell via routes that are inaccessible to nAbs(10–12). However, clinical 
reports using the B cell-depleting antibody rituximab in chronically infected patients showed 
that HCV viremia rose between 10–100 fold following rituximab treatment and returned to 
baseline after reappearance of B cells(13, 14). Similarly, agammaglobulinemic patients have 
been shown to progress more rapidly to cirrhosis(15), even though there are case reports that 
such patients retain the ability to spontaneously clear HCV(16). These clinical observations 
suggest B cells and antibodies play a role in virus control but are not essential for virus 
clearance.
To better define the role of nAbs in HCV infection in model systems that more reliably 
capture some aspects of human physiology, we used three different systems: primary 
hepatocyte cultures, mice expressing the human HCV entry factors and human liver 
chimeric mice. We chose three potent nAbs and assessed their ability to prevent infection in 
all three systems. In addition we tested their effects on established infection in primary 
hepatocyte cultures and liver chimeric mice.
Results
Adeno-associated virus-delivered nAbs neutralize across HCV genotypes
We recently showed that recombinant AAVs are highly efficient vectors for antibody 
delivery after intramuscular injection(17). We constructed AAV8 vectors expressing the 
three HCV nAbs AR3A, AR3B(18) and AR4A(19). Injection of 1011 genome copies of 
AAV-AR3A, -AR3B, AR4A or an anti-HIV control mAb (B12)(20) into the gastrocnemius 
muscle of highly immunocompromised NOD Rag1−/− IL2Rγcnull (NRG) mice or 
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immunocompetent FVB mice resulted in stable, prolonged expression of human IgG 
expression for more than 4 months (Fig 1a & b). It was previously shown that AR3A, 3B 
and 4A potently inhibit HCV entry in cell lines. To test the capacity of in vivo expressed 
human nAb to inhibit HCV infection, we performed in vitro neutralization assays using a 
broad spectrum of intergenotypic chimeras harboring the structural proteins of diverse HCV 
genotypes(21–23). Serum containing anti-HCV nAbs efficiently neutralized most HCV 
genotypes preventing infection of Huh-7.5 hepatoma cells. Of the three nAbs, AR4A was 
the most potent and showed IC50s between 1–3 log10 lower than the previously published 
nAb 3/11(12) (Fig 1c).
Three nAbs protect genetically humanized mice from HCV infection
Having established that the AAV-delivered nAbs could efficiently neutralize HCV in vitro, 
we set out to test their ability to block productive viral entry in vivo. We utilized a 
genetically humanized mouse model based on adenoviral delivery of human HCV entry 
factors into Gt(ROSA)26Sortm1(Luc)Kaelin (Rosa26-Fluc) mice, in which expression of 
firefly luciferase is repressed under steady-state conditions via a loxP site-flanked 
transcriptional stop cassette(24). Rosa26-Fluc mice received nAb expressing AAV-vectors 
(n=12 per group). Subsequent challenge with a bicistronic HCV genome expressing Cre 
recombinase(25) showed that each of the three nAbs alone or as a pool efficiently prevented 
HCV entry as determined by lack of in vivo bioluminescence (Fig 1d). We next examined 
the ability of the nAbs to prevent infection of human liver chimeric mice, the only small 
animal model that robustly supports the entire HCV life-cycle. We constructed a novel 
xenorecipient strain by crossing the fumaryl acetoacetate hydrolase (FAH) knock-out 
allele(26) for 13 generations onto the NRG background. After transplantation of adult 
human hepatocytes into the resulting FNRG mice, mouse liver damage was induced by 
intermittent withdrawal of the protective drug nitisinone and engraftment levels were 
followed over time by measuring human albumin (hAlb) levels in the sera. In closely related 
FAH−/− RAG2−/− IL2Rγnull (FRG) mice, hAlb levels were previously shown to correlate 
with hepatocyte chimerism(27). Although engraftment varied by human donor, FNRG mice 
consistently engrafted to higher levels than FRG mice (Fig S1a)(27, 28). The number of 
human cells could be quantified by flow cytometry for human CD81+ cells in mouse liver 
(Fig S1b), and confirmed by histological staining for FAH (Fig S1c). Having established this 
human liver chimeric FNRG model, we selected animals that were engrafted with adult 
human hepatocytes to hAlb levels > 1 mg/ml (huFNRG), as this had previously been shown 
to correspond to the minimal engraftment level required for HCV permissiveness(27, 29, 
30). To test if the AAV-delivered nAbs could prevent infection, we inoculated huFNRG 
mice with a pool of the three nAb-expressing AAV vectors (AR3A/3B/4A) or the control 
AAV-vector (B12). Sixteen days after AAV injection, the mice displayed serum IgG levels 
between 26–126 μg/ml and 3 days later were infected with a low dose (ca. 3000 copies) of 
HCV genotype 1a clone H77(31). Whereas 2 out of 3 control mice became viremic, none of 
the three mice that received the AR pool displayed viremia (Fig 1e). Because AAV injection 
resulted in a decrease of hAlb serum levels (Fig S2a), which could affect the human graft’s 
ability to support infection, a separate group of huFNRG mice received 3 injection of a pool 
of the purified nAbs or b6 control nAb before challenge with low dose H77. Similar to the 
AAV protection experiments both mice that received the three nAbs remained aviremic, 
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whereas 3 out of 3 control nAb recipients rapidly became viremic. These data show that 
nAbs AR3A, AR3B and AR4A delivered through an AAV vector can effectively neutralize 
HCV across most genotypes and that these nAbs can protect human liver chimeric mice 
from HCV infection with a low dose inoculum.
Abrogation of established HCV infection by nAbs in primary hepatocyte cultures
Given their potent HCV neutralization in vitro and their ability to protect against virus 
challenge in vivo, we tested the ability of these three nAbs to interfere with an established 
HCV infection. HCVcc infection is most reproducibly studied in the Huh7 hepatoma cell 
line and its derivatives, which have two major limitations: proliferation limits the time 
window of any studies, and their impaired innate immunity allows for high replication to 
supra-physiological levels. We therefore chose to study the role of these nAbs in primary 
human fetal liver cultures (HFLCs), in which the hepatocytes have intact innate immunity, 
are non-proliferating and can support HCVcc for several weeks(32). We first performed a 
neutralization assay and found that, similar to results in Huh7 cells, the three purified nAbs 
were able to prevent infection of a cell culture produced HCV reporter virus that secretes 
Gaussia luciferase, termed HCVcc-Gluc(33) (Fig 2a). We then used a ‘therapeutic’ protocol 
in which HFLCs were infected with HCVcc-Gluc and three days later, after replication had 
been established, purified nAbs were added and maintained in the media for the remainder 
of the experiment. Longitudinal luminescence measurements (Fig 2b) or combined 
endpoints from 3 out of 4 livers that supported infection (Fig 2c) showed that nAbs were 
able to interfere with established HCV infection in HFLCs, although not nearly as efficiently 
as the polymerase inhibitor 2′ C-methyl adenosine (2′CMA)(34). These data suggest that 
extracellular spread contributes to maintenance of infection in primary hepatocytes.
HCV infected liver chimeric mice can be cured with nAbs
These in vitro results led us to test the therapeutic effect of nAbs on established HCV 
infection in huFNRG mice. After intramuscular injection of FVB mice with a firefly 
luciferase expressing AAV8, we observed luminescence in both liver and muscle (Suppl Fig 
2b). Intramuscular injection of nAb expressing AAVs into huFNRG (n=8 mice total) 
resulted in a consistent 5–10 fold drop in hAlb serum levels, suggesting that AAV8 vectors 
were also affecting the human xenograft (Fig S2a). We therefore used a passive 
immunization approach to investigate the role of these nAbs on established viremia. We 
infected huFNRG mice with a cell culture derived HCVcc (clone J6/JFH)(23). HCVcc was 
previously shown to be infectious in liver chimeric mice(35) and in vitro which allowed us 
not only to determine viral RNA titers but also to quantify the number of infectious particles 
in limiting dilution assays. Seventeen to 25 days after infection, mice (n=3 for AR pool, n=2 
for b6 controls) were treated with 500 μg of each nAb (AR3A/3B/4A) or 1.5 mg of control 
IgG (b6) every three days, which resulted in high and stable IgG levels (Fig 3a) without 
affecting serum hAlb levels (Fig 3b). nAb treatment suppressed serum infectivity to below 
the limit of detection within one day (Fig 3c). Notably, HCV RNA copy numbers decreased 
in all mice that received the AR pool and fell below the limit of detection between 5 and 11 
days after starting nAb treatment (Fig 3d). These data are in line with previously published 
observations that administration of single dose of a neutralizing antibody reduced the HCV 
viral load below the limit of quantification in a chronically infected chimpanzee(36). We 
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treated HCV-infected human liver chimeric mice for 30 days with nAbs and longitudinally 
monitored their IgG levels in the serum until they became undetectable, 55–69 days after the 
last injection (Fig 3a). A repeat experiment using the same conditions (n=3 for AR pool, n=4 
for b6 controls) again showed the rapid loss of J6/JFH viremia between 4 and 8 days after 
starting nAb injection (Fig 3e). In contrast to a previous study performed in experimentally 
HCV-1a infected chimpanzees (36), J6/JFH viremia did not reappear after the nAb levels 
had fallen below the limit of detection. These data suggest that either the graft was no longer 
permissive to HCV or the virus was indeed cleared and the remaining HCV reservoirs may 
have been eliminated. In order to prove that the human graft could still support HCV 
infection, mice were challenged with a heterologous HCV-1a (clone H77) at ~2×104 copies 
(Fig 3d). Three out of three mice that still had hAlb levels >1 mg/ml became infected, 
illustrating that the lack of viremia was not due to graft loss or non-permissiveness in these 
mice. These results show that three nAbs can efficiently abrogate serum infectivity, which 
leads to rapid loss of viremia that cannot be attributed to graft loss.
We next aimed to determine whether treatment with these three nAbs could abrogate 
viremia in mice infected with a different HCV genotype. Using a similar passive 
immunization strategy as before, H77 viremic huFNRG mice (n=3 for AR pool, n=3 for b6 
controls) were treated either with the pool of three anti-HCV nAbs or an isotype control 
(b6). Similarly to J6/JFH infected mice, all nAb treated mice lost their viremia to below the 
limit of detection, although the difference in viremia with the control mice was less 
pronounced (Fig 3f). However, and in contrast to the rapid disappearance in J6/JFH infected 
animals, it took 15–30 days for H77 infected huFNRG mice to loose their viremia. When 
mice were followed, virus reappeared spontaneously, indicating that although viremia was 
suppressed these mice were not cured by nAb treatment. Sequencing of H77 virus in the 
mice that relapsed did not reveal any escape mutations with the viral envelope associated 
with these nAbs (Fig S3).
Discussion
Vectored immunoprophylaxis has recently been shown to protect mice efficiently against 
HIV or influenza A virus infection(17, 37, 38). Likewise, our results show that potent nAbs 
delivered by AAV vectors can prevent HCV infection, although this is generally much less 
efficient than in vitro neutralization assays may suggest(39, 40). Using a different nAb, 
others have shown that this approach may hold promise for protecting liver grafts from 
reinfection(41). Dosing of nAbs for this application will likely depend on their neutralization 
ability as AbXTL68 did not protect the graft from reinfection even at serum concentrations 
of 200μg/ml(42).
Our findings are the first to show that nAbs can cure liver chimeric mice, even in the 
absence of an adaptive immune system. It is a yet unclear if these findings are specific for 
J6/JFH or generalizable to all HCV isolates. Treatment of liver chimeric mice infected with 
HCV genotype 1a (strain H77) with the pool of antibody also lead decrease of viremia 
below the limit of detection but HCV relapsed spontaneously, which could be explained by 
the shorter nAb treatment duration or by strain differences between J6/JFH and H77. 
Nevertheless, our data imply that HCV must continuously reinfect new hepatocytes in order 
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to sustain viremia. We speculate that the mechanism by which nAbs have the ability to cure 
liver chimeric mice involves the protection of uninfected hepatocytes from becoming 
infected and thereby allowing for clearance of HCV in already infected hepatocytes. Given 
the distinct kinetics in viremia decline between H77 and J6/JFH our findings suggest 
differences in the survival of HCV in hepatocytes, which could be due to cytopathic 
mechanisms or clearance by innate immune pathways. To better dissect the relative 
contributions of these mechanisms it will be important to extend these observations to other 
HCV isolates and genotypes, e.g. HCV genotype 3. This genotype was recently shown to 
require prolonged suppression with a polymerase inhibitor (sofosbuvir) as compared to 
genotype 2 isolates in spite of being equally interferon sensitive (43).
Human primary hepatocyte cultures and humanized mice systems do not completely mimic 
the three-dimensional architecture of liver but they are, apart from chimpanzees, arguably 
the most advanced systems to study HCV infection in its physiological environment. Our 
observations put into question whether cell-to-cell spread is a dominant route for re-
infection, although it is conceivable that this process is compromised and less efficient in 
these experimental systems than in humans. Recent findings demonstrate that broadly nAbs 
can also efficiently suppress viremia in humanized mice(17, 44) and Rhesus monkeys 
infected with HIV or SHIV (45, 46), respectively. Our data extend this work to hepatotropic 
viral infections.
Whether these nAbs will become useful in HCV infected patients will largely depend on the 
ability of upcoming direct acting antivirals(1) to eradicate this infection in every patient. 
Even though we used high doses of nAb and have not determined the minimally effective 
dose at which we can cure liver chimeric mice, it is currently hard to speculate what nAb 
levels are required to prevent infection of hepatocytes in the human liver. Passive 
immunization with a nAb in chimpanzees(36) was slightly above the dose typically used 
clinically for mAb treatments of other conditions. It is therefore feasible that passive nAb 
transfer may be an adjunct therapeutic modality in a subset of HCV infected individuals who 
cannot be cured by upcoming direct acting antivirals.
Materials and Methods
Hepatitis C virus
Plasmids encoding chimeric HCV genomes were linearized with XbaI and transcribed using 
MEGAscript T7 (Ambion). RNA was electroporated into Huh-7.5 cells using a ECM 830 
electroporator (BTX Genetronics) and infectious virus was collected from supernatants 48–
72 h after transfection(23). Serum containing the H77 gt 1a isolate was obtained from 
infected chimpanzees(31).
RT-PCR quantification of HCV RNA
Total RNA was isolated from sera using the RNAeasy kit (Qiagen). HCV genome copy 
number was quantified by one step RT-PCR using Multicode-RTx HCV RNA Kit (Eragen) 
and a light cycler LC480 (Roche Applied Science), according to manufacturers’ instructions.
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Human antibodies
Anti-HCV monoclonal antibodies AR3A, AR3B(18) and AR4A(19) and the anti-HIV 
b6(20) control antibody were generated as previously described.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Prophylactic efficacy of broadly neutralizing anti-HCV antibodies
(a) A pool of AAV vectors expressing the three nAbs AR3A, 3B and 4A or control nAb B12 
were injected intramuscularly in immunodeficient NRG mice and human IgG in mouse 
serum was measured by ELISA (b) FVB mice were injected with AAV vectors expressing 
the nAbs AR3A, 3B, 4A or control nAb B12 or a luciferase expressing AAV (luc2) and 
serum human IgG levels were measured by ELISA. (c) Sera from FVB mice that were 
injected with the AAV-nAb was used for in vitro neutralization assays of intergenotypic 
HCVcc on Huh-7.5 hepatoma cells. Indicated are the genotypes and origin of the structural 
proteins of the challenge strains. IC50 values are depicted at mg/ml of human IgG in mouse 
serum. (d) R26-Fluc mice were administered AAV-nAbs. Once nAb reached peak titers, 
HCV entry factors were adenovirally delivered to the liver and challenged with HCVcc 
expressing Cre recombinase, after which bioluminescence was measured. P values 
comparing B12 to AR antibodies, one way ANOVA. (e) Highly engrafted human liver 
chimeric FNRG mice were either injected with the pool of three nAb expressing AAV 
vectors (n=3) or control B12 AAV (n=3), or received three injections of a pool of purified 
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nAbs (n=2) or b6 control nAb (n=3) and challenged with low dose H77. HCV RNA copies 
in mouse serum were measured by qRT-PCR. P=0.012, two way ANOVA for pooled 
experiments.
de Jong et al. Page 12
Sci Transl Med. Author manuscript; available in PMC 2015 March 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. Combination treatment of primary human hepatocyte cultures with broadly 
neutralizing anti-HCV antibodies abrogate established HCV infection
(a) The three nAbs AR3A, 3B and 4A alone or combined (ARx3) were used for 
neutralization assays on human fetal liver cultures (HFLCs) and compared to the previously 
described nAb 3/11 or control mAb b6. Antibodies at 1μg/ml were added to cultures 1 hour 
prior to infection with HCVcc-GLuc and 6 hours later cultures were washed and maintained 
in media without nAbs for serial luminescence sampling. P values for ARx3 vs b6 on day 2 
and day 9, unpaired t-test. (b) HFLC were infected with HCVcc-Gluc and after three days 
nAbs were added at 1μg/ml, which were maintained in the media for the duration of the 
experiment. (c) Pooled end point luminescence data from 3 out of 4 HFLCs that supported 
viral replication and received nAbs starting three days after infection with HCVcc-Gluc. P 
values by unpaired t-test.
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Figure 3. Combination treatment of human liver chimeric mice with broadly neutralizing anti-
HCV antibodies clears established HCV infection
(a) Highly engrafted huFNRG mice were infected with HCVcc (J6/JFH) and 25 days after 
infection, when all mice were viremic, were injected with either the pool of nAb AR3A, 3B 
and 4A or control mAb b6 at time points indicated by the grey arrows. Human IgG levels in 
mouse serum were determined by ELISA longitudinally until they became undetectable. (b) 
In the same group of mice from figure (a) hAlb levels in mouse serum were measured by 
ELISA for the duration of the experiment. (c) Starting one day after nAb were injected, 
HCV serum infectivity as measured in a limiting dilution assay on Huh-7.5 hepatoma cells. 
(d) HCV RNA was determined in mouse serum by qRT-PCR for the duration of the 
experiment. On day 163 post infection and 56 days after nAb levels had fallen below the 
LOD, the three surviving mice were challenged with HCV (H77) (red arrow) and their 
viremia since rechallenge is depicted by red circles. Each dot represents an individual liver 
chimeric animal. Lowest P value for individual time point is 0.01 on treatment day 13 by 
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unpaired t-test, P=0.067 for experiment by two-way ANOVA. (e) Repeat experiment in 
which J6/JFH viremic huFNRG mice were treated with injections of nAb (grey arrows) and 
HCV RNA serum levels were determined by qRT-PCR. One surviving mouse was 
rechallenged with H77 (red arrow) and serum RNA is depicted in red circle. Lowest P value 
for individual time point is 0.016 on day 39 by unpaired t-test, (f) Combined graph of two 
experiments with H77 infected huFNRG mice. Viremic mice received 5 (squares) or 7 
(circles) injections of nAb (arrows) and HCV RNA in mouse serum was determined by 
qRT-PCR.
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